Burkitt and Burkitt-like lymphoma/leukaemia at Groote Schuur Hospital from 2005 to 2014: a retrospective review

dc.contributor.advisorOpie, Jessica
dc.contributor.authorKoller, Anna J
dc.date.accessioned2022-10-21T13:01:08Z
dc.date.available2022-10-21T13:01:08Z
dc.date.issued2018
dc.date.updated2022-10-20T12:40:23Z
dc.description.abstractIntroduction: South Africa has the highest global burden of human immunodeficiency virus (HIV). The HIV seropositive population is at increased risk of developing non-Hodgkin lymphoma, particularly high grade aggressive subtypes such as Burkitt- and Burkittlike lymphoma (also known as B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma). Methods: Ten year retrospective review of clinico-pathological features and survival of adults with newly diagnosed Burkitt- and Burkitt-like lymphoma at a tertiary hospital in South Africa. Results: Burkitt lymphoma (BL) (n=109) was more frequent than Burkitt-like lymphoma (BLL) (n=41) and at presentation there were no significant differences in HIV prevalence (86% vs 78%); median CD4 count (213 vs 207 cells/μL); bone marrow involvement (49% vs 34%), leukaemic dissemination (37% vs 27%) and most frequent site of diagnosis (abdomen/pelvis; 26% vs 29%), respectively. There were significant differences in median age (34 vs 41 years, p=0.0319), median lactate dehydrogenase levels (2052 vs 869 U/l, p=0.0011) and cerebrospinal fluid involvement (12% vs 0%, p=0.046). 43% of patients with an available HIV viral load result showed virological supression defined as lower than detectable limit (LDL) with the median value also being LDL. The patients that received high dose chemotherapy including high dose methotrexate (112/150; 75%) showed a one-year survival of 62% with no significant difference between Burkitt and Burkitt-like lymphoma (66 months versus 51 months, respectively; p=0.267). Patients with leukaemic presentation showed a significantly lower mean survival of 24 months compared to those without (72 months; p< 0.001). The 2 year survival for the whole group, regardless of type of treatment received, was 40% (95% CI, 32-48%) with a median survival of 7.5 months. Conclusion: This is the largest cohort of Burkitt- and Burkitt-like lymphoma patients described in South Africa. There was a high HIV prevalence. The majority received intensive chemotherapy and survival was comparable to certain well-resourced countries. Leukaemic presentation was frequent and associated with less favourable survival.
dc.identifier.apacitationKoller, A. J. (2018). <i>Burkitt and Burkitt-like lymphoma/leukaemia at Groote Schuur Hospital from 2005 to 2014: a retrospective review</i>. (). ,Faculty of Health Sciences ,Division of Haematology. Retrieved from http://hdl.handle.net/11427/36866en_ZA
dc.identifier.chicagocitationKoller, Anna J. <i>"Burkitt and Burkitt-like lymphoma/leukaemia at Groote Schuur Hospital from 2005 to 2014: a retrospective review."</i> ., ,Faculty of Health Sciences ,Division of Haematology, 2018. http://hdl.handle.net/11427/36866en_ZA
dc.identifier.citationKoller, A.J. 2018. Burkitt and Burkitt-like lymphoma/leukaemia at Groote Schuur Hospital from 2005 to 2014: a retrospective review. . ,Faculty of Health Sciences ,Division of Haematology. http://hdl.handle.net/11427/36866en_ZA
dc.identifier.ris TY - Master Thesis AU - Koller, Anna J AB - Introduction: South Africa has the highest global burden of human immunodeficiency virus (HIV). The HIV seropositive population is at increased risk of developing non-Hodgkin lymphoma, particularly high grade aggressive subtypes such as Burkitt- and Burkittlike lymphoma (also known as B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma). Methods: Ten year retrospective review of clinico-pathological features and survival of adults with newly diagnosed Burkitt- and Burkitt-like lymphoma at a tertiary hospital in South Africa. Results: Burkitt lymphoma (BL) (n=109) was more frequent than Burkitt-like lymphoma (BLL) (n=41) and at presentation there were no significant differences in HIV prevalence (86% vs 78%); median CD4 count (213 vs 207 cells/μL); bone marrow involvement (49% vs 34%), leukaemic dissemination (37% vs 27%) and most frequent site of diagnosis (abdomen/pelvis; 26% vs 29%), respectively. There were significant differences in median age (34 vs 41 years, p=0.0319), median lactate dehydrogenase levels (2052 vs 869 U/l, p=0.0011) and cerebrospinal fluid involvement (12% vs 0%, p=0.046). 43% of patients with an available HIV viral load result showed virological supression defined as lower than detectable limit (LDL) with the median value also being LDL. The patients that received high dose chemotherapy including high dose methotrexate (112/150; 75%) showed a one-year survival of 62% with no significant difference between Burkitt and Burkitt-like lymphoma (66 months versus 51 months, respectively; p=0.267). Patients with leukaemic presentation showed a significantly lower mean survival of 24 months compared to those without (72 months; p< 0.001). The 2 year survival for the whole group, regardless of type of treatment received, was 40% (95% CI, 32-48%) with a median survival of 7.5 months. Conclusion: This is the largest cohort of Burkitt- and Burkitt-like lymphoma patients described in South Africa. There was a high HIV prevalence. The majority received intensive chemotherapy and survival was comparable to certain well-resourced countries. Leukaemic presentation was frequent and associated with less favourable survival. DA - 2018_ DB - OpenUCT DP - University of Cape Town KW - Haematology Pathology LK - https://open.uct.ac.za PY - 2018 T1 - Burkitt and Burkitt-like lymphoma/leukaemia at Groote Schuur Hospital from 2005 to 2014: a retrospective review TI - Burkitt and Burkitt-like lymphoma/leukaemia at Groote Schuur Hospital from 2005 to 2014: a retrospective review UR - http://hdl.handle.net/11427/36866 ER - en_ZA
dc.identifier.urihttp://hdl.handle.net/11427/36866
dc.identifier.vancouvercitationKoller AJ. Burkitt and Burkitt-like lymphoma/leukaemia at Groote Schuur Hospital from 2005 to 2014: a retrospective review. []. ,Faculty of Health Sciences ,Division of Haematology, 2018 [cited yyyy month dd]. Available from: http://hdl.handle.net/11427/36866en_ZA
dc.language.rfc3066eng
dc.publisher.departmentDivision of Haematology
dc.publisher.facultyFaculty of Health Sciences
dc.subjectHaematology Pathology
dc.titleBurkitt and Burkitt-like lymphoma/leukaemia at Groote Schuur Hospital from 2005 to 2014: a retrospective review
dc.typeMaster Thesis
dc.type.qualificationlevelMasters
dc.type.qualificationlevelMMed
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
thesis_hsf_2018_kollerannaj.pdf
Size:
2.02 MB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
0 B
Format:
Item-specific license agreed upon to submission
Description:
Collections